openPR Logo
Press release

US Antidiabetics Drug Market US Antidiabetics Clinical Pipeline Report 2022

07-11-2017 11:14 AM CET | Health & Medicine

Press release from: Kuick Resarch

US Antidiabetics Drug Market US Antidiabetics Clinical

For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990

Report Table of Contents

Antidiabetics: Regimen for Diabetes Mellitus
1.1 Prologue Towards Diabetes
1.2 Preface to Antidiabetics

Antiquity of Managing Diabetes Mellitus
2.1 Trajectory from Diabetes to Insulin
2.2 Historical En Route towards Oral Diabetic Medication

Treatments Available for Diabetes Mellitus
3.1 Non-Pharmacological Approaches for Diabetes Mellitus
3.2 Pharmacological Approaches for Diabetes Mellitus

Cataloguing of Antidiabetic Agents
4.1 Antidiabetic: Oral Agents
4.1.1 Biguanides
4.1.2 Thiazolidinediones (TZDs)
4.1.3 Sulfonylureas
4.1.4 Meglitinides
4.1.5 andalpha;- Glucosidase Inhibitors
4.1.6 Dipeptidyl Peptidase-4 Inhibitor
4.1.7 Bile Acid Sequestrants (BAS)
4.1.8 Dopamine Agonist-2

Antidiabetic: Injectable Drugs
5.1 Insulin: A life saving Modality
5.2 Non-Insulin Alternatives for Diabetes Mellitus

US Diabetes Epidemiology
6.1 Prevalence of Type 1 and 2 Diabetes
6.2 Economic Burden Associated with Type 1 and 2 Diabetes: Productivity Loss and Medical Bills

US Antidiabetics Market Overview
7.1 Antidiabetic Injectable Market Trends in US
7.2 Antidiabetic Oral Drugs Market Trends in US
7.3 Commending Trends of Antidiabetics

US: Key Marketed Antidiabetic Drugs
8.1 Insulin Degludec (Tresiba)- Injection
8.2 Insulin Lispro - Injection
8.3 Insulin Inhalation(Afrezza) - Inhalation
8.4 Insulin Glargine (Toujeo) - Injection
8.5 Insulin Glulisine (Apidra) - Injection
8.6 Insulin Aspart (NovoLog) - Injection
8.7 Insulin Detemir (Levemir FlexTouch) - Injection
8.8 Insulin Glargine (Lantus) - Injection
8.9 Insulin Aspart/Insulin Protamine Aspart (NovoLog) - Injection

US Biosimilar Insulin Market: Glargine Basaglar andndash; The First “Biosimilar” Insulin
9.1 First Insulin Biosimilar
9.2 Impact of Basaglar Launch

US Antidiabetics Drug Market Dynamics
10.1 Accelerative Parameters
10.2 Major Challenges

US Antidiabetics Drug Market Future Prospects

Competitive Landscape
12.1 AstraZeneca
12.2 Bayer
12.3 Boehringer Ingelheim
12.4 Eli-Lilly
12.5 Johnson and Johnson
12.6 Merck
12.7 Novartis
12.8 Novo Nordisk
12.9 Sanofi
12.10 Takeda

Download Report: https://www.kuickresearch.com/report-us-antidiabetics-drug-market-outlook-2022.php

Kuick Research is a market research and analytics company that provides targeted information for critical decisions at business, product and service levels. We are quick, predictive and known by the recommendations we have made in the past. Our result-oriented research methodology offers understanding of multiple issues in a short period of time and gives us the capability to keep you full with loads of practical ideas. By translating research answers into strategic insight and direction, we not only rate the success potential of your products and/or services, but also help you identify the opportunities for growth in new demographies and find ways to beat competition.

Neeraj Chawla
neeraj@kuickresearch.com
KuicK Research
Avanta Business Center 4th Floor,
Statesman House Barakhamba Road,
Connaught Place New Delhi – 110 001, India
+91-11-47067990

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release US Antidiabetics Drug Market US Antidiabetics Clinical Pipeline Report 2022 here

News-ID: 618497 • Views:

More Releases from Kuick Resarch

Lumakras Drug Clinical Insight and Sales Forecast 2026
Lumakras Drug Clinical Insight and Sales Forecast 2026
"Lumakras Drug Clinical Insight and Sales Forecast 2026" Report Highlights: * NSCLC Targeting Lumakras Market Opportunity (US$ Million) * Colorectal Cancer Targeting Lumakras Market Opportunity (US$ Million) * Pharmacokinetics of Lumakras (Sotorasib) * Dosage, Patent and Price Analysis * Lumakras Ongoing Clinical Trials * Global KRAS Protein Inhibitors Clinical Trials Download Report: https://www.kuickresearch.com/report-lumakras-sotorasib-sales-forecast-fda-approved-kras-inhibitor-clinical-trials-non-small-cell-lung-cancer-nslc-g12c-mutation-c30h30f2n6o3-ras-gtpase The rising burden of cancer and the increasing cancer mortality rates possesses an unmet need for the development of novel therapies in the management
Global EZH2 Inhibitor Market Opportunity, Sales and Clinical Trials Insight 2026
Global EZH2 Inhibitor Market Opportunity, Sales and Clinical Trials Insight 2026
"Global EZH2 Inhibitor Market Opportunity, Sales and Clinical Trials Insight 2026" Report Highlights: * Global EZH2 Inhibitor Market Opportunity > US$ 1.2 Billion by 2026 * Tazverik (Tazemetostat) First Approved EZH2 Inhibitor Drug * Dosage, Price and Sales Analysis of Tazverik * Tazverik Sales Opportunity > US$ 900 Million by 2026 * Tazverik Sales Forecast 2021 Till 2026 * EZH2 Inhibitor Clinical Pipeline Overview By Company, Indication and Phase * EZH2 Inhibitor in Clinical Trials: 7 Drugs Download
Global Bispecific Antibody Market Opportunity, Drug Sales, Price and Clinical Trials Insight 2028
Global Bispecific Antibody Market Opportunity, Drug Sales, Price and Clinical Tr …
"Global Bispecific Antibody Market Opportunity, Drug Sales, Price and Clinical Trials Insight 2028" Report Highlights: * Global Bispecific Antibody Market Opportunity: > US$ 20 Billion * Global Bispecific Antibody Market Growth Rate: 100% CAGR (2016 -2021) * Approved Bispecific Antibodies In Market: 4 Antibodies * Detailed Market Sales and Trends Insight Till 2028 * Quarterly and Yearly Sales Insight Of Approved Antibodies Till Q1 2022 * Global and Regional Market Analysis * Approved Drug Sales
Global Fibroblast Growth Factor Receptor Inhibitor Drug Market Opportunity and Clinical Trials Insight 2026
Global Fibroblast Growth Factor Receptor Inhibitor Drug Market Opportunity and C …
"Global Fibroblast Growth Factor Receptor Inhibitor Drug Market Opportunity and Clinical Trials Insight 2026" Report Highlights: * Global FGFR Inhibitors Market Opportunity: > USD 4 Billion by 2026 * Role of FGFR Inhibitors in Cancer Therapy * Global FGFR Market Assessment (US$) by Region and Cancer Type Clinical and Sales Insight on Approved FGFR Inhibitors: 3 (Belvesra, Pemazyre and Truseltiq) * Dosage and Drug Price Insight on Approved FGFR Inhibitors * Comprehensive Clinical Trials Insight

All 5 Releases


More Releases for Antidiabetic

Antidiabetic Biosimilars Market Regional Landscape, Status and Prospects 2020-20 …
Antidiabetic Biosimilars Market Report 2020-2027 includes a comprehensive analysis of the present Market. The report starts with the basic Antidiabetic Biosimilars industry overview and then goes into each and every detail. Antidiabetic Biosimilars Market Report contains in depth information major manufacturers, opportunities, challenges, and industry trends and their impact on the market forecast. Antidiabetic Biosimilars also provides data about the company and its operations. This report also provides information on the
Antidiabetic Drug Market Global Industry Analysis 2018 – 2025
Global Antidiabetic Drug Industry New Study on “2018-2025 Antidiabetic Drug Market Global Key Player, Demand, Growth, Opportunities and Analysis Forecast” added to Wise Guy Reports Database This report studies the global Antidiabetic Drug market status and forecast, categorizes the global Antidiabetic Drug market size (value & volume) by key players, type, application, and region. This report focuses on the top players in North America, Europe, Asia-Pacific, South America, and Middle East &
Global Antidiabetic Thiazolidinediones Market Strategies and Forecasts, 2017 to …
Report Overview: The “Global Antidiabetic Thiazolidinediones Market Research Report” is a professional and in-depth study on the current state of the Antidiabetic Thiazolidinediones Market. The study offers an insight into current and future market trends, key drivers and restraints, market strategies of key market players along with detailed segmentation and forecast. The study offers industry overview by covering basic aspects such as product definition and classification, market size and share of
Antidiabetic Biosimilars Market Expected to Grow Globally
Antidiabetic biosimilars market overview Antidiabetics help control blood glucose levels in diabetic patients. Various types of antidiabetics include biguanides, thiazolidinediones, DPP-IV inhibitors, α-glucosidase Inhibitors, sulfonylureas, insulin, and GLP-1 receptor agonists such as exenatide. A biosimilar product is biological product that is approved on the basis that it is highly similar to a FDA approved biological product known as a reference product. Biosimilar manufacturers need to generate data from lab testing and
03-07-2017 | Health & Medicine
SA-BRC
Antidiabetic Drugs Market and Pipeline Assessment
Diabetes is a major lifestyle disorder affecting millions of individuals globally. The disorder is also linked with other complications such as diabetic retinopathy, diabetic foot ulcers, nephropathy and cardiovascular complications among others. Wide spread global prevalence and rising incidence rate has made the antidiabetic drugs market attractive for pharmaceutical drug manufacturers. Introduction of superior products in the recent past and increasing patient compliance are other factors driving the diabetes treatment
Global Antidiabetic Thiazolidinediones Market Research Report 2017
The research report on the global Antidiabetic Thiazolidinediones market studies the market in the past based on which estimates are presented for the future. The report looks into vital market indicators, trends, and opportunities that will have a bearing on the development of this market. The report begins with an outline of terms and terminologies, classifications, and applications that are standard conventions in the global Antidiabetic Thiazolidinediones market. A glance into